Nomination of Hans von Celsing as new chairman of Peptonic Medical

Stockholm 28th April 2016. - Peptonic Medical AB (publ) (”the Company” or ”Peptonic”) – a company developing pharmaceuticals based on oxytocin  - today announces that the Nomination Committee will propose to the Annual General Meeting on May 19th, that Mr Hans von Celsing be elected Chairman of the Board of Peptonic Medical.

Mr Ron Long, the present Chairman (since 2009), has announced that he is not standing for re-election.

The Nomination Committee also proposes re-election of the board members Prof. Kerstin Uvnäs Moberg, Mrs Nadia Whittley and Prof. Emeritus Andris Kreichbergs.

Further proposals by the Nomination Committee will be presented at the Annual General Meeting.

For more information, please contact;
Johan Inborr, CEO
Telephone:  +46 708 853 893


About Hans von Celsing

During his professional career, Mr Hans von Celsing has gained profound experience in strategic marketing, internationalisation, corporate development and general management. He was Vice President of Elekta (1986 – 1998) responsible for international marketing focussing on USA and Asia. In the late 1990’ies Mr Celsing founded Neuroventure Capital – a venture capital firm in the USA – and several medical and biotech companies such as Plasma Surgical Ltd., of which he was the CEO until 2007. Mr Celsing is chairman of the board of Partner Fondkommission AB (Sweden) and Clinical Laserthermia Systems (publ) AB (Sweden). He is advisor and board member of several Life Science companies including Mevion Medical systems, Inc. (USA) and Gelixir Healthcare Ltd. (UK). Mr Celsing has a wide international contact network within the Life Science industry including clinicians, researchers, investors and industry professionals. Mr Celsing has a MBA degree from Harvard Business School, Boston, USA.

About Peptonic Medical

Peptonic Medical AB (publ) is an innovative Swedish pharmaceutical company developing oxytocin based products e.g. for the treatment of menopausal symptoms, such as vaginal atrophy. Peptonic Medical’s mission is to develop safe and effective drugs based on the well-known beneficial properties of oxytocin.


Documents & Links